# Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

> **NCT01603212** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Vemurafenib
- **DRUG:** IL-2
- **DRUG:** Interferon Alpha-2b

## Key facts

- **NCT ID:** NCT01603212
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-18
- **Primary completion:** 2017-07-05
- **Final completion:** 2017-07-05
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01603212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01603212, "Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT01603212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*